Prime Medicine: Keith Gottesdiener, Jeremy Duffield, Meredith Goldwasser, Andrew Anzalone, Karen Brown
Prime Medicine, a gene editing startup cofounded by the Broad Institute's David Liu, has appointed Keith Gottesdiener as president and CEO. Gottesdiener led Rhythm Pharmaceuticals for nine years, leading the company to FDA submission and approval of IMCIVREE (setmelanotide), the first treatment for rare genetic diseases of obesity. Before joining Rhythm in 2011, Gottesdiener spent 16 years at Merck Research Laboratories, where he held positions of leadership across Merck's early and late clinical development organizations.
The company has also appointed Jeremy Duffield to serve as CSO, Meredith Goldwasser to serve as senior VP of strategy and corporate operations, cofounder Andrew Anzalone to serve as head of the prime editing platform, and Karen Brown to serve as senior VP of intellectual property and legal affairs.
The company's investors and board members include Gottesdiener, F-Prime Capital President and Managing Partner Stephen Knight, ARCH Venture Partners Cofounder and Managing Director Robert Nelsen, GV General Partner David Schenkein, and Beam Therapeutics CEO John Evans.